ES2160643T3 - Composiciones que contienen g-csf y proteina de union al tnf. - Google Patents
Composiciones que contienen g-csf y proteina de union al tnf.Info
- Publication number
- ES2160643T3 ES2160643T3 ES95100661T ES95100661T ES2160643T3 ES 2160643 T3 ES2160643 T3 ES 2160643T3 ES 95100661 T ES95100661 T ES 95100661T ES 95100661 T ES95100661 T ES 95100661T ES 2160643 T3 ES2160643 T3 ES 2160643T3
- Authority
- ES
- Spain
- Prior art keywords
- csf
- pharmaceutically acceptable
- acceptable salt
- binding protein
- tnf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A PRODUCTOS QUE CONTIENEN G-CSF O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO Y UNA PROTEINA AGLUTINANTE TNF, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, SI SE DESEA UN PORTADOR FARMACEUTICAMENTE ADEPTABLE COMO UNA PREPARACION COMBINADA, EL USO DE UN G-CSF O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO , EN LA FABRICACION DE UN MEDICAMENTO PARA LA PROFILAXIS Y/O TRATAMIENTO DE SHOCK SEPTICO DE PACIENTES QUE RECIBEN UNA PROTEINA AGLUTINANTE TNF O UNA SAL FARMACEUTICAMEMTE ACEPTABLE DE LA MISMA, EL USO DE UNA PROTEINA AGLUTINANTE TNF O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, EN LA FABRICACION DE UN MEDICAMENTO PARA LA PROFILAXIS Y TRATAMIENTO DE SHOCK SEPTICO DE PACIENTES QUE RECIBEN UN G-CSF Y UN METODO DE TRATAMIENTO Y/O SHOCK SEPTICO, CUYO METODO COMPRENDE LA ADMINISTRACION TANTO DE PROTEINA TNF O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA Y UN G-CSF O UNA SAL FARMACEUTICAMENTE ACTIVA DEL MISMO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94810059 | 1994-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2160643T3 true ES2160643T3 (es) | 2001-11-16 |
Family
ID=8218199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES95100661T Expired - Lifetime ES2160643T3 (es) | 1994-02-04 | 1995-01-19 | Composiciones que contienen g-csf y proteina de union al tnf. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US5776895A (es) |
| EP (1) | EP0668077B1 (es) |
| JP (1) | JP2765807B2 (es) |
| CN (1) | CN1097468C (es) |
| AT (1) | ATE202709T1 (es) |
| AU (1) | AU693833B2 (es) |
| BR (1) | BR9500436A (es) |
| CA (1) | CA2139385C (es) |
| DE (1) | DE69521536T2 (es) |
| DK (1) | DK0668077T3 (es) |
| ES (1) | ES2160643T3 (es) |
| GR (1) | GR3036774T3 (es) |
| NZ (1) | NZ270422A (es) |
| PT (1) | PT668077E (es) |
| RU (1) | RU2139084C1 (es) |
| ZA (1) | ZA95679B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7705098A (en) * | 1997-05-29 | 1998-12-30 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like protein 8 |
| US6419919B2 (en) * | 1997-11-07 | 2002-07-16 | John D. Mountz | Method for the augmentation of gene expression |
| US6451986B1 (en) * | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| AU766826B2 (en) * | 1998-07-30 | 2003-10-23 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Thymosin beta4 promotes wound repair |
| US20020077276A1 (en) * | 1999-04-27 | 2002-06-20 | Fredeking Terry M. | Compositions and methods for treating hemorrhagic virus infections and other disorders |
| IL157446A0 (en) * | 2001-02-23 | 2004-03-28 | Immunex Corp Immunex Corp | Increased recovery of active proteins |
| US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| AU2003210806A1 (en) * | 2002-03-05 | 2003-09-22 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| RU2207373C1 (ru) * | 2002-04-25 | 2003-06-27 | ООО "Новэнерго" | Способ получения человеческого гранулоцитарного колониестимулирующего фактора |
| US20060002935A1 (en) * | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| US20080008713A1 (en) * | 2002-06-28 | 2008-01-10 | Domantis Limited | Single domain antibodies against tnfr1 and methods of use therefor |
| US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
| JP4980048B2 (ja) | 2003-02-28 | 2012-07-18 | アレス トレーディング ソシエテ アノニム | 腫瘍壊死因子結合タンパク質の液体製剤 |
| JP2010528647A (ja) * | 2007-06-06 | 2010-08-26 | ドマンティス リミテッド | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
| MX344166B (es) | 2008-02-08 | 2016-12-07 | Ambrx Inc | Leptina-polipeptidos modificados y sus usos. |
| CN102159230A (zh) | 2008-07-23 | 2011-08-17 | Ambrx公司 | 经修饰的牛g-csf多肽和其用途 |
| TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
| IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| AU2018348138A1 (en) * | 2017-10-11 | 2020-04-23 | Ambrx, Inc. | Porcine G-CSF variants and their uses |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0396158A1 (en) * | 1985-08-23 | 1990-11-07 | Kirin-Amgen, Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) * | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4985241A (en) * | 1986-11-21 | 1991-01-15 | Cetus Corporation | Therapeutic combination of free-radical scavenger and tumor necrosis factor |
| US5021551A (en) * | 1989-01-18 | 1991-06-04 | Washington University | Method of enhancing peptide immunogenicity |
| US5073627A (en) * | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| EP0939121B2 (de) * | 1989-09-12 | 2007-12-26 | AHP Manufacturing B.V. | TFN-bindende Proteine |
| ES2145744T5 (es) * | 1991-01-18 | 2008-02-01 | Amgen Inc. | Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral. |
| WO1993011793A1 (en) * | 1991-12-17 | 1993-06-24 | Schering Corporation | Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock |
| ATE188610T1 (de) * | 1992-04-30 | 2000-01-15 | Amgen Inc | Methoden zur behandlung von interleukin- 1 und - tumor - nekrose - faktor - verursachten krankheiten |
| DK0642356T3 (da) * | 1992-05-05 | 2003-08-04 | Aeres Biomedical Ltd | Antistoffer mod P-selectin og deres anvendelser |
-
1994
- 1994-12-30 CA CA002139385A patent/CA2139385C/en not_active Expired - Lifetime
-
1995
- 1995-01-19 AT AT95100661T patent/ATE202709T1/de active
- 1995-01-19 DE DE69521536T patent/DE69521536T2/de not_active Expired - Lifetime
- 1995-01-19 DK DK95100661T patent/DK0668077T3/da active
- 1995-01-19 ES ES95100661T patent/ES2160643T3/es not_active Expired - Lifetime
- 1995-01-19 EP EP95100661A patent/EP0668077B1/en not_active Expired - Lifetime
- 1995-01-19 PT PT95100661T patent/PT668077E/pt unknown
- 1995-01-23 US US08/376,267 patent/US5776895A/en not_active Expired - Lifetime
- 1995-01-27 ZA ZA95679A patent/ZA95679B/xx unknown
- 1995-01-27 CN CN95101676A patent/CN1097468C/zh not_active Expired - Fee Related
- 1995-01-30 AU AU11462/95A patent/AU693833B2/en not_active Expired
- 1995-01-31 NZ NZ270422A patent/NZ270422A/en not_active IP Right Cessation
- 1995-01-31 JP JP7013557A patent/JP2765807B2/ja not_active Expired - Fee Related
- 1995-02-02 RU RU95101385A patent/RU2139084C1/ru not_active IP Right Cessation
- 1995-02-03 BR BR9500436A patent/BR9500436A/pt not_active Application Discontinuation
- 1995-05-05 US US08/435,926 patent/US5750503A/en not_active Expired - Lifetime
-
2001
- 2001-10-03 GR GR20010401635T patent/GR3036774T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0668077A1 (en) | 1995-08-23 |
| RU95101385A (ru) | 1996-12-27 |
| JPH07258300A (ja) | 1995-10-09 |
| NZ270422A (en) | 1996-06-25 |
| US5776895A (en) | 1998-07-07 |
| DK0668077T3 (da) | 2001-10-08 |
| JP2765807B2 (ja) | 1998-06-18 |
| ATE202709T1 (de) | 2001-07-15 |
| RU2139084C1 (ru) | 1999-10-10 |
| CN1097468C (zh) | 2003-01-01 |
| AU693833B2 (en) | 1998-07-09 |
| GR3036774T3 (en) | 2002-01-31 |
| CA2139385C (en) | 2001-12-25 |
| EP0668077B1 (en) | 2001-07-04 |
| DE69521536D1 (de) | 2001-08-09 |
| US5750503A (en) | 1998-05-12 |
| CN1111158A (zh) | 1995-11-08 |
| AU1146295A (en) | 1995-08-17 |
| DE69521536T2 (de) | 2002-04-18 |
| PT668077E (pt) | 2001-12-28 |
| ZA95679B (en) | 1995-08-08 |
| CA2139385A1 (en) | 1995-08-05 |
| BR9500436A (pt) | 1995-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2160643T3 (es) | Composiciones que contienen g-csf y proteina de union al tnf. | |
| BG101118A (en) | Therapeutical compounds | |
| UA56989C2 (uk) | ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ | |
| UA39158C2 (uk) | Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі | |
| NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
| BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
| UA41906C2 (uk) | Спосіб лікування неврологічних порушень, викликаних травмами | |
| ATE184792T1 (de) | 2-bromomelatonin zur behandlung von schlafstörungen | |
| DE69400799D1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| RU94020410A (ru) | Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых, пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений | |
| MY111260A (en) | Pharmaceutical composition for the treatment of nicotine dependence | |
| UA41355C2 (uk) | Засіб для лікування нейро-сніду | |
| GR3025488T3 (en) | Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions | |
| NO20000446D0 (no) | Anvendelse av fysiologisk akseptable vanadiumforbindelser, salter og komplekser | |
| EP0347899A3 (en) | Pharmaceutical compositions on egg shell basis and their preparation and use | |
| MX9805441A (es) | Compuestos terapeuticos. | |
| GB2331926A (en) | Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine | |
| EP0744176A3 (en) | Methods for inhibiting bone loss | |
| PL318130A1 (en) | Terpenod derivatives (of sarcodictyine)as antineoplastic agents | |
| TW374085B (en) | Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use | |
| MY104521A (en) | Treatment of depression. | |
| YU13599A (sh) | Primena farmaceutske kompozicije za dobijanje leka u obliku gela | |
| HUP0000110A2 (hu) | Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények | |
| EP0743068A3 (en) | Composition for inhibiting bone loss containing vanadyl sulfate | |
| ATE147978T1 (de) | Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 668077 Country of ref document: ES |